Understanding psychiatric illness through natural language processing (UNDERPIN): Rationale, design, and methodology.

biomarker language machine learning natural language processing (computer science) neurocognitive disorders psychiatric disorders

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2022
Historique:
received: 27 05 2022
accepted: 11 11 2022
entrez: 19 12 2022
pubmed: 20 12 2022
medline: 20 12 2022
Statut: epublish

Résumé

Psychiatric disorders are diagnosed through observations of psychiatrists according to diagnostic criteria such as the DSM-5. Such observations, however, are mainly based on each psychiatrist's level of experience and often lack objectivity, potentially leading to disagreements among psychiatrists. In contrast, specific linguistic features can be observed in some psychiatric disorders, such as a loosening of associations in schizophrenia. Some studies explored biomarkers, but biomarkers have yet to be used in clinical practice. The purposes of this study are to create a large dataset of Japanese speech data labeled with detailed information on psychiatric disorders and neurocognitive disorders to quantify the linguistic features of those disorders using natural language processing and, finally, to develop objective and easy-to-use biomarkers for diagnosing and assessing the severity of them. This study will have a multi-center prospective design. The DSM-5 or ICD-11 criteria for major depressive disorder, bipolar disorder, schizophrenia, and anxiety disorder and for major and minor neurocognitive disorders will be regarded as the inclusion criteria for the psychiatric disorder samples. For the healthy subjects, the absence of a history of psychiatric disorders will be confirmed using the Mini-International Neuropsychiatric Interview (M.I.N.I.). The absence of current cognitive decline will be confirmed using the Mini-Mental State Examination (MMSE). A psychiatrist or psychologist will conduct 30-to-60-min interviews with each participant; these interviews will include free conversation, picture-description task, and story-telling task, all of which will be recorded using a microphone headset. In addition, the severity of disorders will be assessed using clinical rating scales. Data will be collected from each participant at least twice during the study period and up to a maximum of five times at an interval of at least one month. This study is unique in its large sample size and the novelty of its method, and has potential for applications in many fields. We have some challenges regarding inter-rater reliability and the linguistic peculiarities of Japanese. As of September 2022, we have collected a total of >1000 records from >400 participants. To the best of our knowledge, this data sample is one of the largest in this field. Identifier: UMIN000032141.

Identifiants

pubmed: 36532181
doi: 10.3389/fpsyt.2022.954703
pmc: PMC9752868
doi:

Types de publication

Journal Article

Langues

eng

Pagination

954703

Informations de copyright

Copyright © 2022 Kishimoto, Nakamura, Kano, Eguchi, Kitazawa, Liang, Kudo, Sento, Takamiya, Horigome, Yamasaki, Sunami, Kikuchi, Nakajima, Tomita, Bun, Momota, Sawada, Murakami, Takahashi and Mimura.

Déclaration de conflit d'intérêts

TKis has received consultant fees from FRONTEO. YE has received speaker's honoraria from Eisai. TH received speaker's honoraria from Yoishi-tomi. TKik has received speaker's honoraria from Astellas, Dai-nippon Sumitomo, Eli Lilly, Janssen, MSD, Otsuka, Yoshitomi Yakuhin, Pfizer, and Takeda. JM has received speaker's honoraria from Eli Lilly, Janssen, Otsuka, MSD, Shionogi, and Pfizer. MM has received speaker's honoraria from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin. Also, MM received grants from Daiichi Sankyo, Eisai, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi, and Tsumura. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Psychiatry Res. 2021 Oct;304:114130
pubmed: 34332431
Hum Brain Mapp. 2008 Nov;29(11):1265-75
pubmed: 17894392
Schizophr Res. 2021 Feb;228:493-501
pubmed: 32951966
Br J Psychiatry. 2010 Nov;197(5):386-94
pubmed: 21037216
Schizophrenia (Heidelb). 2022 Jul 5;8(1):58
pubmed: 35853912
Nat Med. 2016 Nov;22(11):1248-1255
pubmed: 27783066
PLoS Biol. 2020 Dec 7;18(12):e3000966
pubmed: 33284797
World Psychiatry. 2018 Feb;17(1):67-75
pubmed: 29352548
Neuroimage. 2017 Feb 15;147:736-745
pubmed: 27865923
BMC Med. 2011 Feb 22;9:18
pubmed: 21342500
Transl Psychiatry. 2015 Sep 01;5:e628
pubmed: 26327686
Laryngoscope Investig Otolaryngol. 2020 Jan 31;5(1):96-116
pubmed: 32128436
World Psychiatry. 2014 Oct;13(3):211-23
pubmed: 25273285
NPJ Schizophr. 2015 Aug 26;1:15030
pubmed: 27336038
NPJ Schizophr. 2019 Jun 13;5(1):9
pubmed: 31197184
Early Interv Psychiatry. 2021 Apr;15(2):344-351
pubmed: 32129010
Br J Psychiatry. 2007 Apr;190:326-32
pubmed: 17401039
Am J Psychiatry. 2015 Apr;172(4):363-72
pubmed: 25827034
Nature. 2022 Apr;604(7906):502-508
pubmed: 35396580
Biol Psychiatry. 2017 Jul 1;82(1):26-39
pubmed: 27817844
Schizophr Res. 2008 Jan;98(1-3):201-8
pubmed: 17919890
Psychiatry Res. 2021 Oct;304:114135
pubmed: 34343877
Am J Psychiatry. 2005 Oct;162(10):1785-804
pubmed: 16199825
Schizophr Bull. 2023 Mar 22;49(Suppl_2):S125-S141
pubmed: 36946527
Am J Psychiatry. 2016 Apr 1;173(4):373-84
pubmed: 26651391
Scand J Psychol. 2022 Apr;63(2):91-99
pubmed: 34813111
Transl Psychiatry. 2021 Dec 13;11(1):630
pubmed: 34903724
Schizophr Bull. 2021 Mar 16;47(2):405-414
pubmed: 33025017
Front Hum Neurosci. 2022 Aug 05;16:954898
pubmed: 35992940
Schizophrenia (Heidelb). 2022 Mar 18;8(1):25
pubmed: 35304875
Schizophr Res. 2016 Oct;176(2-3):314-319
pubmed: 27427557
J Commun Disord. 1982 Jun;15(3):167
pubmed: 6124560
Lancet. 2013 Apr 20;381(9875):1371-1379
pubmed: 23453885
Schizophr Res. 2020 Dec;226:158-166
pubmed: 32499162
Psychol Med. 2019 Feb;49(3):440-448
pubmed: 29692287
Stat Med. 1984 Apr-Jun;3(2):143-52
pubmed: 6463451
PLoS One. 2012;7(4):e34928
pubmed: 22506057
Sci Rep. 2019 Oct 2;9(1):14146
pubmed: 31578348
NPJ Schizophr. 2021 May 14;7(1):25
pubmed: 33990615
Schizophr Res. 2023 Sep;259:59-70
pubmed: 35927097
NPJ Schizophr. 2020 Apr 20;6(1):10
pubmed: 32313047

Auteurs

Taishiro Kishimoto (T)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of Medicine, Tokyo, Japan.

Hironobu Nakamura (H)

Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Yoshinobu Kano (Y)

Faculty of Informatics, Shizuoka University, Shizuoka, Japan.

Yoko Eguchi (Y)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Momoko Kitazawa (M)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Kuo-Ching Liang (KC)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Koki Kudo (K)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Department of Neuropsychiatry, St. Marianna University School of Medicine Hospital, Kawasaki, Japan.

Ayako Sento (A)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Akihiro Takamiya (A)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Toshiro Horigome (T)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Toshihiko Yamasaki (T)

Computer Vision and Media Lab (Yamasaki Lab), Department of Information and Communication Engineering, Graduate School of Information Science and Technology, The University of Tokyo, Tokyo, Japan.

Yuki Sunami (Y)

Keio University School of Medicine, Tokyo, Japan.

Toshiaki Kikuchi (T)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Kazuki Nakajima (K)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Masayuki Tomita (M)

Department of Psychiatry, Oizumi Hospital, Tokyo, Japan.

Shogyoku Bun (S)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Department of Psychiatry, Koutokukai Sato Hospital, Yamagata, Japan.

Yuki Momota (Y)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Kyosuke Sawada (K)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Junichi Murakami (J)

Department of Psychiatry, Biwako Hospital, Otsu, Japan.

Hidehiko Takahashi (H)

Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Masaru Mimura (M)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Classifications MeSH